UBS’ Top Tech Based Disruptive Stocks For 2030: Top 29 Stocks

20. Lonza Group AG (OTC:LZAGY)

YTD Share Price Gain: 50.06%

Lonza Group AG (OTC:LZAGY) is a Swiss healthcare company that is one of the biggest in the world. The firm operates primarily in the manufacturing outsourcing segment of the pharmaceutical industry. It enables customers to manufacture biosimilars, genetic therapies, and other associated products. This provides Lonza Group AG (OTC:LZAGY) with a diversified business model that is less reliant on cyclical trends than other high growth firms such as biotechnology companies. This is because biosimilars are cheaper variants of expensive drugs, while gene therapies require extensive development spending. The business model worked in Lonza Group AG (OTC:LZAGY)’s favor in July after its shares jumped by 11% after the firm’s H1 operating income of 893 million francs beat analyst estimates of 802 million. The firm has several catalysts as its products have fueled the development of new drugs such as Alzheimer’s treatments. Additionally, Lonza Group AG (OTC:LZAGY) has struggled because of sluggish demand for its Capsule & Health Ingredients business, and as the firm attunes capacity to match demand, its margins can improve.